Clinical trial
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
NCT00136487 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00136487 |
|---|---|
| Title | Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer |
| Official title | A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib Versus Placebo in Men With Prostate Cancer With Rising PSA Following Prostatectomy or Radiation Therapy |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Pfizer Industry Beth Israel Deaconess Medical Center Emerson Hospital, Concord, MA Brigham and Women's Hospital Hartford Hospital Lowell General Hospital Massachusetts General Hospital M.D. Anderson… |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 85 |
| Start date | Oct 1, 2002 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Dec 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: